Kernicterus due to isoimmunization

Summary

Kernicterus due to isoimmunization (MONDO:0006567) is a disease. A subtype of neonatal anemia — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	kernicterus due to isoimmunization
Mondo ID	MONDO:0006567
DOID	DOID:12043
ICD-10-CM	P57.0
ICD-11	1111245443
NCIT	C101270
SNOMED CT	359007
UMLS	C0270204
MedGen	542597
GARD	0024440
Is cancer (heuristic)	no

Also known as: kernicterus - due to isoimm. · kernicterus due to isoimmunization of fetus or newborn · kernicterus due to isoimmunization of foetus or newborn · kernicterus related to isoimmunization

Disease family

This is a subtype of neonatal anemia. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › hematologic disorder › anemia › neonatal anemia › kernicterus due to isoimmunization

Related subtypes (2): anemia of prematurity, twin to twin transfusion syndrome

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.